Recent Company News

• 08:05 AM ET Jun 02, 2025
  

  Germany's IQWiG says garadacimab shows indication of considerable additional benefit in hereditary angioedema (A$247.80, 0.00)

• 07:48 AM ET May 23, 2025
  

  EU's CHMP adopted a positive opinion recommending the granting of a marketing authorisation for Riulvy

• 06:08 AM ET May 23, 2025
  

  UK's CMA publishes a non-confidential version of its decision to accept commitments from Vifor Pharma in relation to intravenous iron treatments (A$246.38, 0.00)

• 04:08 AM ET May 23, 2025
  

  NICE recommends FILSPARI (sparsentan) as a treatment option for IgA nephropathy (A$246.38, 0.00)

• 04:00 AM ET May 23, 2025
  

  England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy

• 06:03 AM ET May 22, 2025
  

  Aurinia Pharmaceuticals provides update following post-hoc analysis of the 52-week, Phase 3 AURORA 1 study ($8.34, 0.00)

• 05:55 PM ET May 13, 2025
  

  Street Takeaways - CSL impacts from US MFN Policy Developments (A$240.79, 0.00)

• 06:20 PM ET May 07, 2025
  

  CSL downgraded to outperform from high-conviction outperform at CLSA (A$242.98, 0.00)

• 06:35 PM ET May 04, 2025
  

  CSL reaffirms FY NPATA guidance +10-13% @constant currency to $3.2-3.3B (A$256.41, 0.00)

• 11:07 AM ET May 01, 2025
  

  HHS, NIH launch next-generation universal vaccine platform for pandemic-prone viruses